Aortic valve replacement

3 trials 2 recruiting MedDRA PT
3 Registered trials
2 Recruiting
3 Unique sponsors
4 Unique IMPs
0 Commercial trials
Drug classes (ATC)
— ATC code not specified 1
B Haematology (ATC B) 1
N Neurology/Psychiatry (ATC N) 1
A Gastroenterology (ATC A) 1
Mechanism of action (INN-stem analysis)
Unknown / small molecule 2 substances
Supportive / diluent 1 substance
SGLT2 inhibitor 1 substance
Phase III: 1 Phase IV: 2

Filter these 3 trials by country, sponsor, date range and more.

Open in Search → Gap analysis →
Show: 3 trials

Phase III

1 trial
  • Hamilton Health Sciences Corporation Academic
    IMP not specified
    2023-508532-56-00 6 countries 2021 n=975
    Recruiting

Phase IV

2 trials
  • Az Maria Middelares Gent Academic
    LEVOBUPIVACAINE; PIRITRAMIDE; SODIUM CHLORIDE
    2023-509786-21-00 1 country 2024 n=144
    Recruiting
  • Rigshospitalet Academic
    EMPAGLIFLOZIN
    2023-504731-40-01 1 country 2024 n=206
    Ended
Sponsor activity
SponsorTypeTrialsPhasesRecruiting
Hamilton Health Sciences Corporation Academic 1 Phase III 1
Az Maria Middelares Gent Academic 1 Phase IV 1
Rigshospitalet Academic 1 Phase IV 0
New trials by year
2021
1
2024
2
← All indication landscapes